Form 4: LivaNova PLC Director Todd C. Schermerhorn Reports Share Transactions

Director Todd C. Schermerhorn reports acquisition and disposal of LivaNova PLC ordinary shares and restricted stock units.

Summary

• On June 15, 2024, Director Todd C. Schermerhorn acquired 2,680 ordinary shares of LivaNova PLC upon settlement of restricted stock units (RSUs).
• On the same day, 586 shares were disposed of to satisfy tax liabilities at a price of $52.68 per share.
• Following these transactions, Schermerhorn directly owns 6,057 ordinary shares.
• Additionally, Schermerhorn was granted 3,416 RSUs vesting on June 15, 2025.
• Each RSU represents the right to receive one ordinary share of LivaNova PLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and reflect standard compensation practices. There is no indication of unusual or concerning activity.

Positives

• The acquisition of shares through RSU settlement indicates confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax liabilities, while routine, slightly reduces the director's holdings.

Risks

• Continued service is required for the RSUs to vest, introducing a dependency on the director's continued employment.

Future Outlook

The report details future vesting of restricted stock units, contingent on continued service, indicating a long-term incentive structure for the director.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities and beneficial ownership of company stock. It allows investors to monitor insider sentiment and potential alignment with company performance.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies like LivaNova PLC, ensuring compliance with SEC regulations.
• Similar filings are common among peer companies such as Medtronic, Boston Scientific, and Abbott Laboratories, where executives and directors routinely report transactions in company stock.
• The vesting schedules and terms of the RSUs are likely comparable to those offered by other companies in the medical device industry to incentivize and retain key personnel.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The vesting of RSUs incentivizes the director to contribute to the company's long-term success.

Key Dates